| Description | Amatuximab (MORab-009) is a chimeric IgG1/k monoclonal antibody humanized against cell surface mesoleptin (MSLN) with antitumor activity for the treatment of solid tumors. |
| In vitro | Amatuximab (MORAb-009) 是一种鼠-人嵌合型单克隆抗体，对mesothelin (MSLN)有选择性的亲和力。体外实验中，Amatuximab能够诱导抗体依赖的细胞介导的细胞毒性 (ADCC) 来对抗表达mesothelin的肿瘤细胞，并抑制mesothelin阳性肿瘤细胞与表达CA125的肿瘤细胞之间的异型细胞粘连[1]。 |
| In vivo | 在肿瘤异种移植模型研究中，Amatuximab 与化疗的联合治疗比单独使用 Amatuximab 或化疗更能显著降低表达 mesothelin 的肿瘤生长[1]。 |
| Synonyms | MORab-009 |
| molecular weight | N/A |
| CAS | 931402-35-6 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936. 2. Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8. |